Takara Bio Inc 2020 IR
The report highlights Takara Bio's performance for the fiscal year ended March 2020, during which the company launched its new Medium-Term Management Plan 2023 and Long-Term Management Plan 2026. Despite a slight decrease in net sales to ¥34.5 billion due to the divestiture of the AgriBio business, operating income increased by 14.8% to ¥6.27 billion. The company completed the construction of the Center for Gene and Cell Processing II to expand its CDMO business and actively supported COVID-19 testing and vaccine development. Additionally, Takara Bio established the Takara Group Sustainability Policy to address key ESG issues, including reducing CO2 emissions and promoting female participation in management.
Company: Takara Bio Inc
Sector: Health Care
Country: Japan
Year: 2020
Type: IR
Pages: 21
Takara Bio Inc
Corporate Report
The report highlights Takara Bio's performance for the fiscal year ended March 2020, during which the company launched its new Medium-Term Management Plan 2023 and Long-Term Management Plan 2026. Despite a slight decrease in net sales to ¥34.5 billion due to the divestiture of the AgriBio business, operating income increased by 14.8% to ¥6.27 billion. The company completed the construction of the Center for Gene and Cell Processing II to expand its CDMO business and actively supported COVID-19 testing and vaccine development. Additionally, Takara Bio established the Takara Group Sustainability Policy to address key ESG issues, including reducing CO2 emissions and promoting female participation in management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women in Management
Employees